Brigatinib (BRG) vs crizotinib (CRZ) in patients (Pts) with ALK inhibitor-naive advanced ALK plus NSCLC from ALTA-1L
dc.contributor.author | Yang, JCH | |
dc.contributor.author | Kim, HR | |
dc.contributor.author | Ahn, MJ | |
dc.contributor.author | Han, JY | |
dc.contributor.author | Hochmair, MJ | |
dc.contributor.author | Lee, KH | |
dc.contributor.author | Delmonte, A | |
dc.contributor.author | Campelo, MRG | |
dc.contributor.author | Kim, DW | |
dc.contributor.author | Felip, E | |
dc.contributor.author | Califano, Raffaele | |
dc.contributor.author | Spira, A | |
dc.contributor.author | Gettinger, S | |
dc.contributor.author | Tiseo, M | |
dc.contributor.author | Haney, J | |
dc.contributor.author | Kerstein, D | |
dc.contributor.author | Popat, S | |
dc.contributor.author | Camidge, DR | |
dc.date.accessioned | 2019-12-09T17:08:12Z | |
dc.date.available | 2019-12-09T17:08:12Z | |
dc.date.issued | 2019 | en |
dc.identifier.citation | Yang JCH, Kim HR, Ahn M-J, Han J-Y, Hochmair MJ, Lee KH, et al. O1-4-2 [Encore]Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK+ NSCLC from ALTA-1L. Annals of Oncology. 2019;30(Supplement_6). | en |
dc.identifier.doi | 10.1093/annonc/mdz339.006 | en |
dc.identifier.uri | http://hdl.handle.net/10541/622523 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1093/annonc/mdz339.006 | en |
dc.title | Brigatinib (BRG) vs crizotinib (CRZ) in patients (Pts) with ALK inhibitor-naive advanced ALK plus NSCLC from ALTA-1L | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | National Taiwan University Hospital, Taiwan | en |
dc.identifier.journal | Annals of Oncology | en |
dc.description.note | en |